A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia
Categories (click each to see list of all clinical trials associated with that category): Bone Marrow Transplant (BMT)/Graft Versus Host Disease (GVHD)
Current Status: Open to accrual
Phase: III
Principal Investigator: Al-Kadhimi, Zaid
Contact Information:
Penny Hardiman, RN
402-559-4135
penny.hardiman@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT02665065#eligibility
Summary
Primary Outcome:Durable Complete Remission (dCR) [ Time Frame: 6 months from time of initial CR or CRp ] Defined as CR or CRp lasting 180 days or more from time of initial CR or CRp is documented with evidence of subsequent relapse
Secondary Outcome:Overall Survival (OS) at 1 year from randomization [ Time Frame: 1-year following randomization ] Patient overall survival